TickerFacts.

Upstream Bio, Inc. (UPB): Shareholders' Equity

Annual figures by period end, from SEC filings.

$339.77M
As of 2025-12-31
$270.96M
As of 2026-06-30
$469.85M2023-12-31: -$123.13M2024-12-31: $469.85M2025-12-31: $339.77M$339.77M
2023-12-31 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31$339.77M-27.7%2026-03-26, Balance as of period end
2024-12-31$469.85Mn/m2026-03-26, Balance as of period end
2023-12-31-$123.13Mn/a2025-03-12, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
Upstream Bio, Inc. (UPB)2025-12-31$339.77M-27.7%
Cartesian Therapeutics, Inc. (RNAC)2025-12-31-$126.24Mn/m
Xenetic Biosciences, Inc. (XBIO)2025-12-31$7.40M+23.1%
TherapeuticsMD, Inc. (TXMD)2025-12-31$26.88M-1.8%
GeoVax Labs, Inc. (GOVX)2025-12-31$3.83M-24.2%
Camp4 Therapeutics Corp (CAMP)2025-12-31$47.70M-24.5%
Marker Therapeutics, Inc. (MRKR)2025-12-31$16.80M-9.5%
Korsana Biosciences, Inc. (KRSA)2025-12-31$9.09M+2.7%
Dianthus Therapeutics, Inc. (DNTH)2025-12-31$493.40M+40.0%

Compare UPB, RNAC, XBIO, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗